Pharmaceutical Exporter from India to Germany.

Yes. Every commercial batch entering the EU must be released by a Qualified Person at an EU-licensed site. We work with QP service providers licensed in Germany and the Netherlands who receive the Indian batch, review the full manufacturing and analytical documentation against the EU dossier, take retained samples, and issue the QP release certificate before the stock is moved into the Apotheken or Krankenhausapotheken supply chain.

Yes, through the Decentralised or Mutual Recognition Procedure with BfArM as either RMS or CMS. The typical active-review clock is 210 days plus clock-stops for queries, and we build the eCTD dossier from the Indian manufacturing partner's CTD, including bioequivalence data, stability to ICH climate zones II/IVa, and a German-language SmPC, PIL and Fachinformation. Centralised EMA filings are reserved for molecules that require them.

§73 Abs. 3 of the Arzneimittelgesetz permits single-patient import of a product not licensed in Germany, on written request from the treating physician via a German pharmacy. We handle the Indian-side paperwork (CoA, batch certificate, manufacturing licence extract), the QP check on arrival, and dispatch into the requesting Apotheke, typically 7 to 14 days from order depending on molecule and cold-chain requirement.

Every prescription pack destined for the German market carries a unique 2D Data Matrix (GTIN, serial, batch, expiry) and a tamper-evident seal per the Falsified Medicines Directive, uploaded to the securPharm national repository before release. We coordinate serial-number ranges with the German Marketing Authorisation Holder or our QP partner, and verify pack status is 'active' in securPharm before the stock leaves the bonded site.

For innovative products falling under AMNOG, the G-BA benefit-assessment dossier is typically led by the Marketing Authorisation Holder's German medical affairs team. Our role is on the manufacturing and supply side: CMC sections of the dossier, EU-GMP supply Germany from India with validated stability and capacity statements, and batch-release continuity through our QP network. For pure generics, the Festbeträge reference-price system and AOK-style rebate tenders are the relevant economic layer.

Frankfurt (FRA) is the default pharma lane from Mumbai, with the Pharma.Aero-certified, CEIV Pharma-accredited cargo handling at Fraport; direct BOM–FRA sector is 8 to 9 hours in the air and 3 to 5 days door-to-door including QP release and bonded put-away. Leipzig (LEJ) serves as a secondary air hub. Sea freight is routed via Hamburg or Bremerhaven for ambient palletised volume, typically 26 to 32 days door-to-door.

Yes. German-language Beipackzettel (patient information leaflet), Fachinformation (SmPC for prescribers) and carton copy are mandatory for any prescription product on the German market and are produced against the approved BfArM dossier. Translation is done through our regulatory partner in Germany and reviewed by a native-speaker regulatory affairs officer before artwork is locked and sent to the Indian manufacturing partner for printing.

Three routes, picked by molecule and existing authorisation status. Decentralised Procedure (DCP) with BfArM as Reference Member State (RMS) or as a Concerned Member State (CMS) is the most common route for a generic without any existing EU authorisation, with a 210-day active-assessment clock plus clock-stops. Mutual Recognition Procedure (MRP) reuses an existing EU marketing authorisation already held in another EU Member State, with shorter timelines because the dossier has already been assessed. Centralised Procedure via EMA is mandatory for biotechnology-derived medicines, advanced-therapy medicinal products (ATMPs), orphan medicines, and certain new oncology / HIV / diabetes / autoimmune molecules under the EMA Annex; rights to market across all 27 EU member states + Iceland + Liechtenstein + Norway. We pick the route at quote stage based on the molecule's existing EU authorisation history and the destination volume.

BfArM accepts dossier submissions through the Common European Submission Platform (CESP), the EU-wide gateway operated by HMA (Heads of Medicines Agencies). Files are submitted in eCTD format (Module 1 country-specific German content, Modules 2-5 technical) signed with the applicant's eIDAS qualified electronic signature. CESP routes the submission to BfArM (or PEI for biologicals) automatically. The same gateway handles variations, renewals and PSUR submissions throughout the product's lifecycle. We prepare the eCTD baseline locally in Mumbai with our German-language regulatory partner so the CESP upload is a one-pass file transfer rather than a build-as-you-go process that risks gateway-timeout errors at the larger Modules 3 and 5 file sizes.

Conditionally accepted under collaborative regulatory reliance. BfArM, PEI and the EMA participate in the EU's mutual-recognition framework with PIC/S (Pharmaceutical Inspection Co-operation Scheme) and the EU-FDA Mutual Recognition Agreement, plus reliance on EU-competent-authority inspections (ANSM France, AEMPS Spain, AIFA Italy, IGZ Netherlands, MPA Sweden). An Indian site holding a recent EU-GMP certificate from any EU competent authority typically does not face a fresh BfArM on-site inspection for routine-list molecules. First-time registration of any biological, vaccine, ATMP or oncology biological at PEI may trigger an on-site inspection by PEI's own inspectors, with inspection costs borne by the applicant. We share the relevant EU-GMP certificate and inspection date in every dossier so the BfArM/PEI reviewer can apply the reliance assessment cleanly.

BfArM applies the EMA-aligned variation framework: Type IA (notification-only, take effect immediately, file the notification within 12 months and the BfArM clock is administrative, not assessment), Type IB (60 days for BfArM review under the "tell, wait, do" rule if BfArM raises no objection), and Type II (major change, 60-90 days for BfArM review, sometimes 180 days where an updated inspection or extended scientific assessment is needed). Typical examples: pack-size change (Type IA), excipient supplier change with no specification impact (IB), specification change or manufacturing-site transfer or new strength (II). We file variations through CESP using the same eCTD baseline as the original DCP/MRP submission, so the variation dossier reuses the source pack without retrofit cost.

AMNOG (Arzneimittelmarktneuordnungsgesetz, 2010) requires every new active substance launched in Germany to undergo a Gemeinsamer Bundesausschuss (G-BA) benefit-assessment within 12 months of launch, based on a dossier the Marketing Authorisation Holder submits to G-BA describing additional benefit vs the appropriate comparator. The G-BA decision (Zusatznutzen rating from "major" to "no proof") feeds the reimbursement-price negotiation between the MAH and the GKV-Spitzenverband (statutory health insurance umbrella). M Care's role in AMNOG is on the manufacturing and supply side: CMC continuity statements, EU-GMP supply assurance from the Indian partner, batch-release capacity through our QP network for the negotiated launch volume. For generics, the Festbeträge reference-price system and AOK / Barmer rebate-tender awards are the relevant economic gate rather than AMNOG.